Targeting solute carriers to modulate receptor–ligand interactions

Trends in Pharmacological Sciences, vol. 43, pp. 358–361

Abstract

Solute carrier transporters (SLCs) limit receptor activation via uptake of extracellular ligands. Novel concepts are emerging that describe the modulation of intracellular and plasma membrane receptors by ligand influx and efflux via SLCs, respectively. Here, we evaluate recent insights and provide an outlook for developing potential therapeutic strategies.

Authors 4

1. Hubert J. Sijben Aachen Division of Drug Discovery and Safety Leiden Academic Centre for Drug Research

   Leiden University

   Affiliation as printed

   Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

2. Giulio Superti‐Furga

   Austrian Academy of Sciences · Medical University of Vienna · CeMM Research Center for Molecular Medicine

   Affiliation as printed

   CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, 1090 Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria

   CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, 1090 Vienna, Austria

   Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria

3. Adriaan P. IJzerman Aachen Division of Drug Discovery and Safety Leiden Academic Centre for Drug Research

   Leiden University

   Affiliation as printed

   Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

4. Laura H. Heitman corresponding Aachen Division of Drug Discovery and Safety Leiden Academic Centre for Drug Research

   Leiden University · Oncode Institute

   Affiliation as printed

   Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands; Oncode Institute, Leiden, The Netherlands. Electronic address: l.h.heitman@lacdr.leidenuniv.nl

   Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands

   Oncode Institute, Leiden, The Netherlands